Rheumatoid Arthritis: Severity Classification, Factors Responsible, Pathophysiology, Current and Herbal Treatment by Galatage, Sunil T. et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books








Severity Classification, Factors 
Responsible, Pathophysiology, 
Current and Herbal Treatment
Sunil T. Galatage, Aditya S. Hebalkar, 
Sayali S. Gaikwad, Pranav S. Kumbhar, Nikhil N. Patil, 
Kranti D. Desai, Sonam U. Kanekar, Samruddhi S. Kadam, 
Rushikesh S. Sansare, Sonali S. Sansare and Suresh G. Killedar
Abstract
Rheumatoid Arthritis is the autoimmune disorder occurs due to the change 
in life style, improper diet plans, smoking, excessive alcohol consumption etc. It 
generally affects the joints and creates swelling and severe pain in joints which 
leads to further destruction of bone and cartilages. Due to autoimmune responses 
the factors like Tumor Necrosis Factor-α, Interleukins-1 are introduced to synovial 
and synovial membrane which creates the swelling and pain. These factors further 
produce reactive oxygen species and inducing osteoclasts which destruct the bone 
and cartilages. Along with the drugs the several natural herbal treatments are also 
available for the treatment of rheumatoid arthritis. This includes varies medicinal 
plants form which acacia species is more potent and efficient. Acacia Senegal is 
the plant which blocks the receptors and decreases the level of tumor necrosis 
factor-α. Present work on rheumatoid arthritis mainly covers classification, factors 
responsible, pathophysiology, severity, current treatment and its drawbacks, herbal 
treatment and its benefits in treatment of Rheumatoid Arthritis.
Keywords: rheumatoid arthritis, swelling, interleukins, cartilages, interleukins,  
bone erosion, Acacia Senegal, herbal treatment
1. Introduction
Bones are the prime constituents of Human Body as they have been affected by 
chronic diseases [1]. Nowadays, in the developed countries about 1% of population 
is suffering from the bone related chronic disease; Rheumatoid Arthritis (RA) [2]. 
Rheumatoid arthritis is a chronic autoimmune inflammatory disease predominantly 
characterized by inflammation of connective tissue that lines the inside of the joint 
capsule. Commonly RA It is accompanied by multi-organ disorders, along with 
pain, swelling, and stiffness of multiple joints. Joint destruction progresses rapidly 
resulting in irreversible dysfunction and deformation of the affected joints. Large 
Rheumatoid Arthritis
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Target population (Who should be tested?) Patients who
1. Have at least one joint with definite clinical synovitis (swelling)*
2. With the synovitis not better explained by another disease
Classification criteria for rheumatoid arthritis-based on the score
A Joint involvement Score
1 large joint 0
2–10 large joints 1
1–3 small joints 2
4–10 small joints 3
>10 joints 5
B Serology (depends on the results of tests)
Negative RF and ACPA 0
Low positive RF and low positive ACPA 2
High positive RF and high positive ACPA 3
C Acute-phase reactants (depends on the results of tests)
Normal CRP and normal ESR 0
Abnormal CRP or abnormal ESR 1




Rheumatoid arthritis classification criterion in 2010 [13].
Sr. No. Criterion Definition
1. Morning stiffness It is defined as the uncomfortable state occurred at 
morning time in and around the joints, lasting for at 
least 1 hour before maximal improvement.
2. Arthritis of 3 or more joints areas Physician have to observe the occurrence of swelling or 
fluid in soft tissue simultaneously in more than 3 joints. 
Examples are PIP, MCP, wrist, elbow, knee, ankle and 
MTP joints.
3. Symmetric arthritis When the same joint on the both side of body is 
involved.
4. Arthritis of hand joints In this at least a small part of a single hand is involved.
5. Rheumatoid nodules As physician observed, Subcutaneous nnodules, over 
bony prominences, or in juxtaarticular regions.
6. Serum rheumatoid factor Demonstration of abnormal amounts of serum 
rheumatoid factor by any method for which the result 
has been positive in less than 5% of normal control 
subjects.
7. Radiographic changes Radiographic changes typical of rheumatoid arthritis on 
poster anterior hand and wrist radiographs, which must 
include erosion or unequivocal bony decalcification 
localized in or most marked adjacent to the involved 
joints (osteoarthritis changes alone do not qualify).
Table 1. 
Criteria for classification of RA revised by American rheumatism association in 1987 [12].
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numbers of peoples facing swelling and severe pain due to RA. There are several 
factors which leads to RA, but genuine causes are still unknown [3]. Generally 
occurrence of RA is due to genetic alterations and environments causes [4]. These 
genetic alterations are due to factors like change in lifestyle, smoking, autoimmune 
response excess alcohol consumption, etc. [5]. According to World health organism 
the Rheumatoid Arthritis is defined as autoimmune, inflammatory disease that is 
responsible for pain, stiffness, swelling, which further leads to the impairment in 
its function [6]. These are generally occurs in the joints like carpals, metacarpals 
and knee joints [7]. The respective joints which are suffered are becoming inflamed, 
leading to tissue damage, chronic pain, unsteadiness, and deformity [8]. Also the 
RA affects the eyes, lungs, heart, and mouth [9]. The untreated RA further leads 
to the bone and cartilage destruction and uncertain and sudden fractures [10]. 
The symptoms and further destruction can be reduced and prevented by proper 
treatment but total curation of RA is not yet invented [11]. Rheumatoid Arthritis 




The worldwide scientists and researchers are only known that autoimmune 
response is responsible for the RA and genuine pathophysiology is still unknown 
[15]. So the different researcher gives different pathophysiologies. Form them the 
important two are explained below [16]. Generally the joints are mostly affected 
like wrist, knees, hand, ankles and feet. It is the autoimmune disorder means the 
body attacked by itself [17]. The immune system attacks to the joints and organ 
tissue [18]. The WBCs moves into the joint. They release chemicals called cytokines 
which attacks the cell of the synovial membrane. These chemicals cause synovial 
cells to release the other chemicals. They also cause synovial membrane to grow 
Figure 1. 
General classification of rheumatoid arthritis.
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new blood vessels and form a thicken area called pannus [19]. As the pannus grows 
day by day it invades and destructs the cartilages. Inflammation induces the fluid 
accumulation in the joint which lead to the further swelling and pain [20]. Due to 
this the free space between joints get decreases and form ankylosis and in some 
cases bones get fused to each other causing permanent disability of mobility of it 
(Figure 2) [21].
Another pathophysiology describes that around 7–65% of undifferentiated 
arthritis get converted into rheumatoid arthritis. In this the characteristic inflam-
matory mediators like monocytes and lymphocytes leaves the circulation and 
migrate to the synovium due to any autoimmune response occurs due to the reasons 
still unknown [22]. As the monocytes matured, the number of macrophases in 
the synovium gets increases. Some macrophages remain in the synovium further 
recruiting inflammatory cells. Other migrates towards or onto the hyperplastic 
synovial lining and get joined to the macrophage like and fibroblast like synovial 
sites. Simultaneously the APCs interact with the activated T-cells present, signaling 
the macrophages and they get bind to the synovial sites to release the inflammatory 
mediators like TNF-α and IL-1. TNF-α and IL-1 signals the additional recruitment 
of additional inflammatory cells from the blood, these cells also recruits the PMNs 
which migrate towards and crosses the hyperplastic synovial lining and enters in 
the joint space [23]. PMN releases the protease and ROs which get destroys nearby 
cartilages. Fibroblasts like synovial sites releases the additional proteases like 
MMP-1 and MMP-3 which also destructs the cartilages [24]. The fibroblast like 
synovial sites may release RANKL leading to nearby osteoclast which destruct the 
bones. This is the how RA get induced and develops [25].
4. Biosynthesis of TNF-α protein
On the cell membrane there are several receptors are present. There is a type 
known Toll-like receptors (TLR4) present on the cell membrane. When the lipo-
polysaccharides (LPS) are going to be attached to lipopolysaccharide binding pro-
teins (LBP) and is transferred to CD14 (receptors of TNF superfamily). It activates 
two pathways from which one is for internucleus transcription of TNF mRNA and 
another is for intranucleus translation of TNF-α protein. In first activated pathway 
Figure 2. 
Pathophysiology of rheumatoid arthritis.
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through IRAK (Interleukin1 receptor associated kinase) and IKK (inducible I 
kappa β kinase) activates the p50 and p65 the NFkβs (nuclear factor kappa light 
chain enhancer). These NFkβs then get entered into the nucleus. Then due to them 
first transcription is done and pre-TNF mRNA forms which further converts into 
TNFmRNA by splicing maturation process. And then the TNFmRNA is exported to 
intranucleus portion. On other hand in the second pathway the MKK3,6 (mitogen 
activated protein kinase kinase) is activated and further activates p38. p38 then 
activates two constituents Mk2 (mitogen activated protein kinase activated protein 
Figure 3. 
Biosynthesis of TNF-α protein.
Figure 4. 
Risk factors responsible for rheumatoid arthritis.
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kinase-2) and MNK1 (a kinase of the MAPKKADK family that can regulate transla-
tion). They further promoted the formation of TTP (tristetroproline-zinc finger 
protein 36 homolog), hnRNP-A1 (heterogeneous nuclear ribonucleoprotein A1), 
TIA-1 (T-cell restricted Intracellular antigen 1), elF4E (eukaryotic translation initia-
tion factor 4E), HuR. These all are further going in the process of translation along 
with the TNFmRNA and forms the TNF-α protein (Figures 3 and 4) [26].
5. Risk factors responsible for rheumatoid arthritis
5.1 Genetic factors
If a person having occurrence of Rheumatoid Arthritis is his/her previous 
generations then he/she will be at high risk of availability of same disorder [27].
5.2 Hormones
There are some hormones present in human body which are responsible for RA. 
According to CDC (Centre of Disease control and prevention) the women are at high 
risk of RA as compare to the men [28]. The hormones responsible are as follows:
a. Estrogen: Estrogen is a type of sex hormone which is also present in the male 
also, according to previously done research works it is proved that after meno-
pause the estrogen received at replacement therapy is responsible for occur-
rence of RA [29].
b. Testosterone: The disturbed level of testosterone in human body is leads to the 
RA. Many clinical studies are done on this case in 2018 [30].
c. Menopause: The females after menopause having high physical stress and leads 
to disability in physical functions which results in symptoms of RA [31].
5.3 Age
According to CDC, persons in and after 60’s are at more risk to suffering from 
RA [32].
5.4 Smoking
Smoking is a very dangerous addictive habit generally occurs in male, it leads 
to lots of life threatening diseases like lung cancer. It induces the autoimmune 
responses due to which RA happens [33].
5.5 Stress
As like above mentioned smoking the stress is also affects the immune system of 
human body and induces autoimmune responses which leads to traumatic experi-
ences and further RA [34].
5.6 Obesity
Nowadays the world’s most common disorder is obesity which create the various 
metabolic syndromes which leads to inflammation and further the RA [35].
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5.7 Early life factors
According to the CDC the persons having low economic conditions are having 
higher exposure to RA. It is directly or indirect links to the factor Diet [36].
5.8 Previous history
The person having any history of occurrence of arthritis in his old generations 
then he/she might be on the high risk of arthritis.
5.9 Diet
Improper diet which leads to change in lifestyle is also responsible for occurrence 
of the rheumatoid arthritis [37–39].
6. Treatment
There are lot of research works done but yet no any proper treatment were found 
that will cure Rheumatoid Arthritis totally from its roots. Only some drugs were 
Figure 5. 
Current treatment for rheumatoid arthritis.
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evolved which reliefs from some of the symptoms and prevent further destructions 
of bones and cartilages [40, 41]. These drugs are having the side effects too. Some 
methods and aspects of treatment are as follows (Figure 5):
6.1 Natural treatment
There are varies species of plants available worldwide that are used for treatment 
of Rheumatoid Arthritis. Some majorly used plants are mentioned below with their 
Scientific name, Family, Local name (Table 3).
As like above mentioned plants there are many more plants are available with 
anti-rheumatic activity. The most efficient plant species is seems to be the Acacia 
species. Generally the Acacia species are act as a COX-1 and COX-2 inhibitors. 
The in vitro assay of Acacia species proved that they shows the COX-1 and COX-2 
inhibitory action. Some species having activity with the extracts described below. 
The most potent species of Acacia is Acacia Senegal which is also called as Gum 
Arabica or Hashab gum. It is having properties or activity that decreases the level of 
TNF-α, ESR, SJC, TJC, VAS, DAS28 (Table 4) [42–44].
6.2 Non-drug treatment
6.2.1 Physiotherapy
Physiotherapy is one of the most prominent and painless technique to get rid off 
from rheumatoid arthritis which comes under non-drug treatment. It is a vital part 
Sr. No. Scientific Name Family Local Name
1 Alpinia galangal Linn. Zingiberaceae Arattai, Perarattai
2 Anacyclus pyrethrum Asteraceae Akkirakkaram
3 Aphanamixis polystachya wall Meliaceae Malampuluvan
4 Aquilaria agallocha Thymeleaceae Agalicundanam
5 Argemone Mexicana Papaveraceae Kutiyotti
6 Callicarpa macrophylla Vahl Verbenaceae Nallai
7 Capparis deciduas Capparaceae Senkam, Sirakkali
8 Cardiospermum halicacabum Linn. Mudukkottam Modikkottan
9 Carthamus tinctorium Linn. Asteraceae Senturakam, kusumba
10 Cassia fistula Caesalpiniaceae Konnai
11 Catunaregum spinosa Rubiaceae Madkarai
12 Citrullus colocynthis Linn. — Paitummatti
13 Commiphhora myrrha Nees Burseraceae Vellaippapolam
14 Commiphara wightii Burseraceae Kiluvai
15 Cordial dichotoma Forst — Naruvili
16 Coriandrum sativum Apiaceae Kottamalli
17 Euphorbia neriifolia Linn. Euphorbiaceae Saturakkalli
18 Euphorbia ligularia Euphorbiaceae Llaikkalli
19 Ficus benghalensis Moraceae Alamaram
20 Flacourtia jangomas Flacourtiaceae Vaiyyankarai
Table 3. 
Natural herbs used in effective treatment of rheumatoid arthritis.
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in the whole lines of treatment of rheumatoid arthritis in cases of both acute and 
chronic condition. These are several program as follows which are included in the 
physiotherapy as follows:
1. Exercise – the regular exercise like walking, running, cycling, yoga, swimming 
etc. are very useful aspects of physiotherapy.
2. Physical therapy – the physical therapy included the use of heat and ice along 
with the electrical stimulation in transcutaneous region, exercise having range 
of motion, gentle strengthening moves, etc. which helps to decreases the  
swelling and pain.
3. Occupational therapy – the person who helps the patients of rheumatoid ar-
thritis in occupational therapy is called as occupational therapist whose work 
is to identify and detect the problem faced by the modify it as the patient feels 
compatible while dealing with these stuffs.
4. Mind – body therapies – these therapies are used to stabilize the mind and 
thinking of patient and to give rest to his/her body. It includes deep abdominal 
breathing, meditation, muscle relaxation in progressive manner, visualization, 
tai chi, counseling, acupuncture, hot and cold comfort bath, massage and rest.
6.2.2 Surgery
This is the last line of treatment in rheumatoid arthritis. Drugs are only able to 
reduce the symptoms and give relief from pain. But when the situation of patient 
get critical then the surgery becomes mandatory. And this helps in restoration of 
joint and its movements. There are several surgeries like spinal surgery, hip replace-
ment surgery, knee replacement surgery, total joint replacement, carpal tunnel 
release, synovectomy, bone and joint fusion surgery [45–47].
6.3 Drug treatment (modern treatment strategies)
In the drug treatment there are two categories in drugs one is DMARDs which 
is major one and another is Adjuvant drugs which is minor one. The main aim of 
this type of drug treatment is to minimize the inflammation, swelling and pain in 
joints of patient. Also it prevent the further bone erosion and damage of articular 
cartilage after the diagnosis. The drug treatment helps the patient to get relief from 
the deadly pains and stabilize the joint functions and its motility.






A. nilitica (L.) Wild. ex Del. subsp. Tomentosa Bark 46.3 ± 6.7 83.9 ± 4.2
Leaf 78.1 ± 0.3 89.5 ± 1.8
A. nubica Benth Bark 39.6 ± 5 90.4 ± 4.6
Leaf 77.4 ± 4.6 92.7 ± 0.2
A. senegal (L.) Wild. Subsp. senegal Bark 17.5 ± 7.1 91.6 ± 5.9
Leaf 71.9 ± 7.43 93.7 ± 3.4
Table 4. 




DMARDs are referred as Disease Modifying Anti-Rheumatoid Drugs or 
(SAARDs) Slow Acting Anti-Rheumatoid Drugs. From the very old days the first 
line of treatment for rheumatoid arthritis was use of NSAIDS, but recently after lots 
of research on various aspects of rheumatoid arthritis the DMARDs are considered 
to be the first line of treatment as a Modern Treatment for Rheumatoid Arthritis. It is 
better to take more than two drugs of same class i.e. DMARDs alternatively because 
the DMARDs loses its potency with prolonged use. DMARDs are of two types one 
is non-biological type and another is biological type as follows: (Following are the 
types or classes of drugs are explained in the form of their examples).
6.5 Non biological drugs
6.5.1 Immunosuppressant
6.5.1.1 Azathioprine
Azathioprine get converted into the 6-Mercaptopurine by the enzyme thiopu-
rine methyl transferase (TPMT) and suppress the cell mediated immunity very 
potently. It comes under purine synthtase inhibitor class. The Azathioprine selec-
tively affect differentiation and function of T-cells and natural killer cells. It also 
minimizes the inflammation. In the modern treatment the Azathiprine is given with 
the corticosteroids due its steroid sparing effect (Figure 6).
6.5.1.2 Methotrexate
It is the dihydrofolate reductese inhibitor which has very prominent immuno-
suppressant and tremendous anti-inflammatory property. Methotrexate helps the 
patient to get relief very rapidly within 3 to 6 weeks. Therefore, it is more prefer-
able than any other medicaments in initial treatment. Among all the DMARDs 
methotrexate is the first choice due to its most predictable response and long term 
sustainability. Mostly combined regimens of DMARDs includes methotrexate. If 
the above DMARDs are failed to treat the patient then the immunosuppressant like 
cyclosporine, chlorambucil, cyclophosphamide were used [48].
6.5.2 Other immunomodulators
6.5.2.1 Sulfasalazine
It is the drug of choice in second line of treatment or in combined regimen with 
methotrexate. Sulfasalazine is synthesized from sulfapyrindine and 5-amino sali-
cylic acid, it have the potent anti-infalmmatory activity which is used in bowl and in 
ulcerative colitis. The exact mechanism of action is still not known. The SSZ variant 
of sulfasalazine was designed in 1938 specially for the treatment of rheumatoid 
arthritis. The main pharmacological effects of sulfasalazine are affecting the bacte-
rial flora, inflammatory cell function and immunological process. The approximate 
mechanism of action of Nf-kB, osteoprotegerin (OPG) and RANK-ligand.
6.5.2.2 Hydroxychloroquin/chloroquin
Hydroxychloroquin is the drug used mostly to treat the malaria patient. Along 
with malaria it is also used in treatment of rheumatoid arthritis due to its low 
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toxicity. Its exact mechanism of action is not elaborated yet but approximately it 
reduces the monocyte interleukin-1 along with inhibition of B-lymphocytes.  
Also it have some proposed mechanism of actions like stabilization of lysozomes 
and processing of antigens. This drug is advised only when small quantity of 




TNF-α (Tumor Necrosis Factor alpha) is the most important responsible factors 
for the cause of rheumatoid arthritis. So, in modern treatment the mostly used drug 
is TNF-α inhibitors (Figure 7).
Figure 6. 




It is the subcutaneous injection which is composed of fusion protein of  
TNF – Receptor with FC portion of human IgG1. It binds and blocks the TNF-α 
from activating the TNF-α receptors. There are also some drugs available in the class 
of TNF-α inhibitors like infliximab, adalimumab, certolizumab, golimumab.
6.6.3 Interleukin-1 (IL-1) inhibitors
Along with TNF-α, IL-1 is also the important responsible protein in etiol-
ogy of rheumatoid arthritis. The IL-1 inhibitors are like Anakinra, Rilonacept, 
Canakinumab.
Figure 7. 
Biological drugs for treatment of rheumatoid arthritis.
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6.6.4 Anakinra
In 2001, USA and in 2002, Europe first launched this drug which was specially 
derived for rheumatoid arthritis treatment. This bind and blocks the IL-1 to present 
the further joint damage. Initially Anakinra was the main drug of modern treat-
ment but nowadays it is used more in the treatment of the gout and polyserosities as 
compare to rheumatoid arthritis.
6.6.5 Interleukin-6 (IL-6) and interleukin-6 receptor inhibitor
In 1986 scientists was found the key cytokine moiety in the pathogenesis of 
rheumatoid arthritis named IL-6 which having prominent pro-inflammatory activ-
ity. To prevent this IL-6 inhibitors are derived.
6.6.6 Tocilizumab
It is the very first humanized recombinant IgG1 monoclonal antibody which 
get binds to both the types of IL-6 that is soluble and membrane bound to block its 
action and to minimize the initiated inflammatory response.
6.6.7 Sarilumab
It is the second human immunoglobulin G1 IL-6 receptor antagonist monoclonal 
antibody working as same as above mentioned tocilizumab [50].
6.7 Anti CD-20 antibody
6.7.1 Rituximab
From 2006 onwards the rituximab was used in treatment of rheumatoid arthritis 
along with methotrexate and TNF-α as a combined dose regimen. It is the chimeric 
murine-human monoclonal antibody which get binds to CD-20 receptors which 
inhibits the circulation of B cells and activations of T cells.
6.8 CD-80/86: CD 28 inhibitors
6.8.1 Abatacept
It is the recombinant fusion protein given by in infusion and subcutaneous 
which is combination of part of FC domain of human IgG with extracellular 
domain of T cell inhibiting receptor CTLA4. It get binds to CD 80 and CD 86 along 
with CD 28 to inhibit the second signal of T cell co stimulations. It was given under 
combined dose regimen with methotrexate.
6.8.2 JAK: inhibitors
JAK (Janus-Kinase) is the cytoplasmic protein tyrosine kinase which is respon-
sible for the signal transduction of the nucleus from the gamma chain (common) 
of plasma membrane receptor for the IL-2, IL-4, IL-7, IL-9, IL-15, IL-21. These all 
interleukins are the very important medications of many pro-inflammatory and 
inflammatory components like cytokines, interferons, interleukin-6. So to prevent 
and inhibit this the JAK inhibition are approved by FDA in 2012 in USA and by 
Rheumatoid Arthritis
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EMA in European Union in 2017. The two main JAK inhibitors are tofacitinib and 
bacricitinib. Tofacitinib is the inhibitor for JAK 1 and JAK 3 with large affinity and 
for JAK 2 and tyrosine kinase 2 in with little affinity. It is used for severe arthritis 
either in monotherapy or with methotrexate. Also the bacricitinib is also works as 
same as tofacitinib [51].
6.9 Adjuvant drugs
6.9.1 Corticosteroids
Glucocorticoid is the most potent corticosteroid that can used at any stage in 
treatment of rheumatoid arthritis in modern treatment. It is used to minimize the 
swelling, pain and slowing down the joint destruction along with preventions of 
bone erosion as it have promising anti-inflammatory and immunosuppressant activ-
ity. Though it is administered in combination with first and second line drugs in the 
form of intraarticular injection it does not give total relief from rheumatoid process.
7. Drawbacks of modern treatment strategies
Among the DMARDs the dihydrofolate reductase immunosuppressant are 
causes the bone marrow depression, oral ulceration and G.I. upset. Methotrexate 
causes the liver cirrhosis when its is used in prolonged therapy. It is contraindi-
cated in pregnancy, breast feeding, liver disease, active infection, leucopenia and 
peptic ulcer, hematological abnormalities, congenital deformities in pregnancy. 
Sulfasalazine produces neutropenia, thrombocytopenia, hepatitis, idiosyncrasy, 
skin reaction, pheumonitis, agranulocytosis, hemolytic anemia, reduction in 
male fertility. The regular blood count monitoring is necessary in case of this 
treatment. In case of treatment with Immunomodulators; due to prolonged use 
of hydroxychloroquin get accumulated in tissue and produces toxicity and other 
adverse effects like retinal damage, corneal opacity, rashes, graying of hairs, 
irritable bowel syndrome, myopathy, neuropathy. TNF-α blockers causes red-
ness, itching and swelling at injection site along with occasional chest infection. 
Higher use of adjuvant drugs leads to patient becoming the steroid dependent 
along with over threathening disease and vasculities. On other hand IL-1 causes 
itching, pain and redness at the site of injection along with severe infections, 
decrease in WBC and platelets in some patients. The IL-6 inhibiting causes 
diverticulitis, purulent peritonitis, lowering the GI perforation, fistula, abscess, 
neutropenia, thrombocytopenia, hyperlipidemia, infections, liver enzyme 
elevation. Abatacept is not able to give with TNF-α inhibits due to do rise of 
severe infections. Also it causes hypersensitivity, anaphylaxis, anaphylactoid 
reactions, tuberculosis, sepsis. There is no any study available regarding that 
whether the drug is safe for pregnant woman or not. The anti-CD 20 antibodies 
are responsible for headache, fever, skin rashes, dyspnea, hypotension, nausea, 
rhinitis, pruritus and mild angioedema along with hypogammaglobinemia. 
There is very limited information related to the administration of this drug to 
pregnant woman. Along with this the JAK-inhibitors produces the hypotension, 
nausea, diarrhea, increase in LDL, HDL and total cholesterol, vein thrombosis, 
pulmonary embolism, upper respiratory tract infections. The JAK-Inhibitors are 
contraindicated in the patients with neutropenia, tuberculosis, severe infections, 
severe liver impairment and pregnancy. To overcome this all drawbacks the use 
of natural treatment on large scale is prefereable [52].
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8. Severity
The Rheumatoid Arthritis is most likely available disease now in all over the 
world [53]. There is one survey run in Canada on “Self-reported prevalence and 
number of individuals with arthritis by age and sex, household population aged 
15 years and older”, in 2007 and 2008 which is represented graphically below [54]. 
From the above graph it is clearly shown that the severity of RA is increased day by 
day and year by year in Canada in year 2007 and 2008 (Figure 8) [55].
9. Severity and survey in India
In India also the severity of RA is on large scale and the yearly surveys are 
done for its analysis and data were published. Following are some surveys made 
in various regions of India for RA by Indian Physicians and expert people of RA 
(Table 5) [56, 57].
Figure 8. 
Survey on rheumatoid arthritis in Canada.
Sr. No. Year Area of survey Patient population size recorded
1 1988 Pune (Maharashtra) 110
2 1992 Nationwide 11931
3 1993 5 villages of Ballabhgarh township (Haryana) 39826
4 1994 West Bengal 4800
5 1995 Uttar Pradesh 74
6 2001 Bhigwan, Pune (Maharashtra) 5998
7 2003 Jammu (Jammu and Kashmir) 1014
8 2003 Lucknow (Uttar Pradesh) 148
9 2005 New Delhi 81
10 2005 Manipal (Karnataka) 141




The Rheumatoid Arthritis is chronic autoimmune disorder occurs worldwide 
due to change in life style, unavailability of proper diet, hereditary characters, 
excessive alcohol consumption, etc. However the actual reason is still unknown. 
The Rheumatoid Arthritis is generally occurs in joints causing swelling and severe 
pain which further leads to destruction of bones and cartilages. First line treatment 
mainly includes synthetic drugs like Disease Modifying Anti-Rheumatic Drugs; 
monoclonal antibodies are now available for treatment for Rheumatoid Arthritis. 
Current treatment is not able to completely cure the Rheumatoid Arthritis form its 
roots as it has certain side effects such as bone marrow depression, oral ulceration, 
G.I. upset, skin reaction, pheumonitis, retinal damage, hypersensitivity, anaphy-
laxis, anaphylactoid reactions etc. So patients suffering from it require complete 
cure from it which leads to utilization of natural herbs for treatment of RA. Herbal 
treatment includes medicinal plants along with Acacia species which are mostly 
preferable because they are more potent, efficient; reduce pain and inflammation 
precisely along with lesser side effects. Medicinal herbs act is a blockers or inhibi-
tors for the arthritis inducing factors. Due potential benefits of herbal medicines 
there is tremendous interest growing in medicinal herbs and there is need for more 
investigate in-vivo applicability. Currently severity of RA is rapidly growing day by 
day. Best current management pathway for RA contains identification, utilization 
of medicinally potent herbs along with physiotherapy which mainly include regular 
exercise like walking, running, cycling, yoga, swimming and acupuncture. As RA 
chronic disorder which creating permanent disability to joints which may leads to 
life threatening conditions; social awareness about RA and its remedies are needed.
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Sr. No. Year Area of survey Patient population size recorded
12 2006 New Delhi 211
13 2007 New Delhi 66
14 2007 Northern India 96
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